Figure 1.
A. Point prevalence of dabigatran and rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation. B. Point prevalence of dabigatran and rivaroxaban among anticoagulated chronic hemodialysis patients with atrial fibrillation, by drug dose.